<?xml version="1.0" encoding="UTF-8"?><!-- generator="WordPress/2.5.1" -->
<rss version="0.92">
<channel>
	<title>Evidence &#38; Performance Blog</title>
	<link>http://blog.evidence-performance.com</link>
	<description></description>
	<lastBuildDate>Fri, 02 Jan 2009 08:52:11 +0000</lastBuildDate>
	<docs>http://backend.userland.com/rss092</docs>
	<language>en</language>
	
	<item>
		<title>Assessing the performance of CROs</title>
		<description><![CDATA[Assessing the performance of CROs
Pharmaceutical and biotech companies want to speed up the research and development process whilst adhering to stricter guidelines. That&#8217;s why CRO&#8217;s are primarily selected on their scientific expertise and the cost/value ratio.
If R&#38;D companies have always had a ‘feeling&#8217; about their CRO, they are now more and more looking for facts [...]]]></description>
		<link>http://blog.evidence-performance.com/2009/01/02/performance-cro/</link>
			</item>
	<item>
		<title>Happy New Year 2009 !!!</title>
		<description><![CDATA[Dear Readers and Contributors
As the end of the year is coming closer, we would like to write a few personal words.
Thanks to all of you, we were able to set up a great group, and we were able to launch our blog in June 08!
Your experience and advices helped us to grow and to continuously provide [...]]]></description>
		<link>http://blog.evidence-performance.com/2008/12/30/happy-new-year-2009/</link>
			</item>
	<item>
		<title>eClinical Technologies perspective : Interview with a dynamic CTO</title>
		<description><![CDATA[ 
As part of our ever lasting goal to provide you with the most accurate information, we are pleased to share with you some words we exchanged with Vincent Wautelet, CTO of a young yet professionnal EDC Company in Belgium.

 

[ADS] Can you please tell us about your experience with regards to innovative technologies dedicated [...]]]></description>
		<link>http://blog.evidence-performance.com/2008/12/19/eclinical-technologies-perspective/</link>
			</item>
	<item>
		<title>Simulated Strategies for better Trials</title>
		<description><![CDATA[In September&#8217;s edition, Applied Clinical Trials has published an thorough article on computer simulation models that would have a direct benefit on patient recruitment and site selection.
You can read the article online, by clicking on this link.
This article demonstrates, once again, the specific need of pharmaceutical companies to manage their clinical trial in a cost [...]]]></description>
		<link>http://blog.evidence-performance.com/2008/11/26/simulated-strategies-for-better-trials/</link>
			</item>
	<item>
		<title>Pharma. Challenges: Executive Interview with Dr. Pierre Le Sourd</title>
		<description><![CDATA[We had the pleasure to meet Doctor Pierre Le Sourd, former President of Bristol Myers Squibb France and most recently President of the Leem (The French Pharmaceutical Companies Association).
Mr Le Sourd brings us 30 years of pharmaceutical experience to help us understand current challenges and perspectives in this industry. 

 
[ADS] According to you, what [...]]]></description>
		<link>http://blog.evidence-performance.com/2008/10/23/pharma-challenges-executive-interview-with-dr-pierre-le-sourd/</link>
			</item>
	<item>
		<title>CDISC and HL7 “BRIDG”ed together</title>
		<description><![CDATA[ 
We almost all know what CDISC is. It is a consortium that develops and maintains clinical data standards, like SDTM (Study Data Tabulation Model) and ODM (Operational Data Modeling).
The purpose of SDTM is to store clinical trial data, in XPT format together with standardized and organized metadata.
The purpose of ODM is to store not only [...]]]></description>
		<link>http://blog.evidence-performance.com/2008/10/18/cdisc-and-hl7-%e2%80%9cbridg%e2%80%9ded-together/</link>
			</item>
	<item>
		<title>Clinical Trial Performance Metrics Event !</title>
		<description><![CDATA[The 6th annual conference will take place in London from January 27th to 29th, 2009!
We are of course looking forward for this unique event in Europe, as its focus is Performance, and Metrics used to accelerate development, improve quality and streamline decision making.
By joining the performance metrics event, you will:
- benefit from the experience of [...]]]></description>
		<link>http://blog.evidence-performance.com/2008/10/15/clinical-trial-performance-metrics-event/</link>
			</item>
	<item>
		<title>Datatrak adds Site Performance to its eClinical Platform</title>
		<description><![CDATA[ 
Datatrak is highlighting ease of access to site performance metrics as a key differentiator as it launches the latest version of its platform eClinical product suite.
The latest version of eClinical suite is tracking metrics on investigative site performance in clinical trials.
This should be critical information to sponsors in their choice of sites &#8220;as efficient [...]]]></description>
		<link>http://blog.evidence-performance.com/2008/10/05/datatrak-adds-site-performance-to-its-eclinical-platform/</link>
			</item>
	<item>
		<title>The Life Sciences Information Technology Global Institute</title>
		<description><![CDATA[LSIT (Life Sciences Information Technology)is a non-profit organization bringing together several industries to build the first Good Informatics Practices (GIP) guidance document to assist IT in 5 areas: compliance, standards, best practices, risk mitigation and return of investment. GIP is the guidance for improving quality and trust of IT within life sciences and healthcare.
GIP guidance [...]]]></description>
		<link>http://blog.evidence-performance.com/2008/09/18/lsit/</link>
			</item>
	<item>
		<title>Phase Forward buys into next-generation IRT with Clarix acquisition</title>
		<description><![CDATA[ 
US-Based Phase Forward, specialized in data management solutions for clinical trials and drug safety pays US$40 millions for Clarix LLC, a provider of fully Web-integrated interactive response technology (IRT).
Clarix&#8217;s IRT will be combined with Phase Forward&#8217;s InForm electronic data capture (EDC) solution and its Empirica Safety Suite for pharmacovigilance and adverse event reporting.
Clarix&#8217;s fully [...]]]></description>
		<link>http://blog.evidence-performance.com/2008/09/09/phase-forward-clarix-acquisition/</link>
			</item>
</channel>
</rss>
